New Vernon Capital Holdings II LLC Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

New Vernon Capital Holdings II LLC raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5,531.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 327,860 shares of the biopharmaceutical company’s stock after acquiring an additional 322,038 shares during the quarter. New Vernon Capital Holdings II LLC’s holdings in Catalyst Pharmaceuticals were worth $7,951,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Catalyst Pharmaceuticals by 5.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock valued at $1,749,000 after buying an additional 3,800 shares in the last quarter. Hancock Whitney Corp increased its holdings in shares of Catalyst Pharmaceuticals by 1.4% in the first quarter. Hancock Whitney Corp now owns 38,847 shares of the biopharmaceutical company’s stock valued at $942,000 after purchasing an additional 525 shares during the period. Clark Capital Management Group Inc. raised its position in Catalyst Pharmaceuticals by 17.9% during the 1st quarter. Clark Capital Management Group Inc. now owns 244,995 shares of the biopharmaceutical company’s stock worth $5,941,000 after buying an additional 37,262 shares during the last quarter. Advisors Asset Management Inc. raised its holdings in Catalyst Pharmaceuticals by 7.7% during the first quarter. Advisors Asset Management Inc. now owns 178,866 shares of the biopharmaceutical company’s stock worth $4,338,000 after purchasing an additional 12,819 shares in the last quarter. Finally, EP Wealth Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 14.3% in the 1st quarter. EP Wealth Advisors LLC now owns 12,035 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 1,504 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total transaction of $42,272.00. Following the transaction, the insider directly owned 41,081 shares of the company’s stock, valued at $1,085,360.02. The trade was a 3.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Steve Miller sold 115,000 shares of the company’s stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $20.28, for a total value of $2,332,200.00. Following the completion of the transaction, the insider directly owned 949,663 shares in the company, valued at $19,259,165.64. This represents a 10.80% decrease in their position. The disclosure for this sale can be found here. Insiders sold 167,894 shares of company stock worth $3,434,690 over the last 90 days. Insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 0.1%

Shares of NASDAQ CPRX opened at $19.80 on Friday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.00 and a 52-week high of $26.58. The firm’s 50-day moving average price is $20.89 and its two-hundred day moving average price is $22.44. The stock has a market capitalization of $2.42 billion, a P/E ratio of 12.00, a P/E/G ratio of 0.80 and a beta of 0.85.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 9th. Zacks Research cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Finally, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, June 5th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $33.20.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.